DK0625355T4 - Tablet med forbedret biotilgængelighed indeholdende dichlormethylendiphosphonsyre som virksomt stof - Google Patents

Tablet med forbedret biotilgængelighed indeholdende dichlormethylendiphosphonsyre som virksomt stof

Info

Publication number
DK0625355T4
DK0625355T4 DK93111827T DK93111827T DK0625355T4 DK 0625355 T4 DK0625355 T4 DK 0625355T4 DK 93111827 T DK93111827 T DK 93111827T DK 93111827 T DK93111827 T DK 93111827T DK 0625355 T4 DK0625355 T4 DK 0625355T4
Authority
DK
Denmark
Prior art keywords
tablet
active substance
diphosphonic acid
improved bioavailability
dichloromethylene diphosphonic
Prior art date
Application number
DK93111827T
Other languages
English (en)
Other versions
DK0625355T3 (da
DK0625355T5 (da
Inventor
Walter Preis
Bernd Muesel
Guenter Dr Neugebauer
Rolf-Dieter Dr Gabel
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25927331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0625355(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE9307393U external-priority patent/DE9307393U1/de
Priority claimed from DE19934322057 external-priority patent/DE4322057A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of DK0625355T3 publication Critical patent/DK0625355T3/da
Publication of DK0625355T4 publication Critical patent/DK0625355T4/da
Application granted granted Critical
Publication of DK0625355T5 publication Critical patent/DK0625355T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK93111827T 1993-05-15 1993-07-24 Tablet med forbedret biotilgængelighed indeholdende dichlormethylendiphosphonsyre som virksomt stof DK0625355T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE9307393U DE9307393U1 (de) 1993-05-15 1993-05-15 Tablette mit verbesserter Bioverfügbarkeit, enthaltend Dichlormethylendiphosphonsäure als Wirkstoff
DE19934322057 DE4322057A1 (de) 1993-07-02 1993-07-02 Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff

Publications (3)

Publication Number Publication Date
DK0625355T3 DK0625355T3 (da) 1995-12-27
DK0625355T4 true DK0625355T4 (da) 2003-10-06
DK0625355T5 DK0625355T5 (da) 2003-12-01

Family

ID=25927331

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93111827T DK0625355T5 (da) 1993-05-15 1993-07-24 Tablet med forbedret biotilgængelighed indeholdende dichlormethylendiphosphonsyre som virksomt stof

Country Status (25)

Country Link
US (1) US5650168A (da)
EP (2) EP0697890A1 (da)
JP (1) JP3699110B2 (da)
KR (1) KR100263284B1 (da)
CN (1) CN1041797C (da)
AT (2) ATE128363T1 (da)
AU (1) AU687744B2 (da)
BR (1) BR9307859A (da)
CA (1) CA2162470C (da)
CZ (1) CZ287984B6 (da)
DE (1) DE59300688D1 (da)
DK (1) DK0625355T5 (da)
ES (1) ES2065313T5 (da)
FI (1) FI111519B (da)
GR (2) GR940300095T1 (da)
HU (1) HU220872B1 (da)
IL (1) IL106743A (da)
NO (1) NO307548B1 (da)
NZ (1) NZ254765A (da)
PL (1) PL173026B1 (da)
RU (1) RU2134103C1 (da)
SK (1) SK281193B6 (da)
TW (1) TW350772B (da)
UA (1) UA39884C2 (da)
WO (1) WO1994026310A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94926C (fi) * 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
CZ20002567A3 (cs) * 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
AP2006003602A0 (en) * 2003-09-19 2006-04-30 Sun Pharmaceutical Ind Ltd Oral drug delivery system
US10213387B2 (en) 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US10226428B2 (en) 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US7151400B2 (en) * 2004-07-13 2006-12-19 Taiwan Semiconductor Manufacturing Company, Ltd. Boost-biased level shifter
CN100370972C (zh) * 2006-01-10 2008-02-27 北京申科联华科技有限公司 一种具有益气养阴、活血复脉功效的片剂及制备方法
AU2008283297A1 (en) * 2007-08-02 2009-02-05 Teijin Pharma Limited Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism
CA2715584A1 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd. Oral controlled release tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2813121A1 (de) * 1977-03-29 1978-10-12 Procter & Gamble Verwendung von dichlormethan-diphosphonatverbindungen bei der bekaempfung von collagen-erkrankungen und zur wundheilung
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ES2040733T3 (es) * 1986-12-20 1993-11-01 Boehringer Mannheim Gmbh Medicamentos que contienen clodronato y procedimiento para su preparacion.
DE3804686A1 (de) * 1988-02-15 1989-08-24 Henkel Kgaa Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
FI83421C (fi) † 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
DK0573604T3 (da) * 1991-02-26 1995-05-29 Procter & Gamble Pharma Fremgangsmåde til behandling af osteoporosis
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss

Also Published As

Publication number Publication date
PL307133A1 (en) 1995-05-02
TW350772B (en) 1999-01-21
EP0625355B1 (de) 1995-09-27
IL106743A0 (en) 1993-12-08
RU2134103C1 (ru) 1999-08-10
WO1994026310A1 (de) 1994-11-24
ES2065313T1 (es) 1995-02-16
IL106743A (en) 1999-11-30
SK281193B6 (sk) 2001-01-18
CA2162470C (en) 1998-06-16
HU9403160D0 (en) 1995-02-28
EP0697890A1 (de) 1996-02-28
JP3699110B2 (ja) 2005-09-28
SK4895A3 (en) 1997-01-08
NZ254765A (en) 1997-02-24
AU687744B2 (en) 1998-03-05
GR940300095T1 (en) 1995-01-31
FI945313A (fi) 1994-12-13
UA39884C2 (uk) 2001-07-16
HUT70214A (en) 1995-09-28
GR3017547T3 (en) 1995-12-31
PL173026B1 (pl) 1998-01-30
JPH08509697A (ja) 1996-10-15
CN1041797C (zh) 1999-01-27
NO944405L (no) 1994-11-24
ATE128363T1 (de) 1995-10-15
CN1095267A (zh) 1994-11-23
FI111519B (fi) 2003-08-15
DE59300688D1 (de) 1995-11-02
KR960702322A (ko) 1996-04-27
ES2065313T5 (es) 2004-01-01
KR100263284B1 (ko) 2000-08-01
EP0625355A1 (de) 1994-11-23
FI945313A0 (fi) 1994-11-11
US5650168A (en) 1997-07-22
ES2065313T3 (es) 1995-12-01
DK0625355T3 (da) 1995-12-27
HU220872B1 (en) 2002-06-29
BR9307859A (pt) 1996-01-09
EP0625355B2 (de) 2003-06-25
NO307548B1 (no) 2000-04-25
AU4702093A (en) 1994-12-12
CA2162470A1 (en) 1994-11-24
CZ10095A3 (en) 1995-10-18
DK0625355T5 (da) 2003-12-01
AT128U1 (de) 1995-03-27
NO944405D0 (no) 1994-11-17
CZ287984B6 (cs) 2001-03-14

Similar Documents

Publication Publication Date Title
NO179911C (no) Optisk aktivt 5H-pyrrolo[3,4-bÅpyrazinderivat samt farmasöytiske preparater inneholdende derivatet
KR970006279A (ko) 약제학적 활성 성분으로서의 6-디메틸아미노메틸-1-페닐-사이클로헥산 화합물
DK0625355T5 (da) Tablet med forbedret biotilgængelighed indeholdende dichlormethylendiphosphonsyre som virksomt stof
NO864879D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiasolforbindelser.
ATE222243T1 (de) Pharmazeutisch wirksame benzochinazolin verbindungen
NO900032L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tiazol-forbindelser.
ITMI931014A0 (it) Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
FI890123A0 (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia indolyylipiperidiiniyhdisteitä
DK0868184T3 (da) Mikrogranula med forlænget frigivelse indeholdende diltiazem som aktivt stof
NO934145L (no) Farmasöytiske forbindelser
TR24383A (tr) Konsantre yuezey aktif madde granuelleri yapmaya mahsus yoentem
KR950704292A (ko) 약학적 활성을 가진 이환식 화합물(Bicycylic Compounds with Pharmaceutical Activity)
DK524489A (da) Fremgangsmaade til fremstilling af biologisk aktive forbindelser, specielt enzymer
DE69315062T2 (de) Triazol-ring enthaltende phosphonsäurederivate als herbizide
NO940844D0 (no) Farmasöytisk aktive hydroksykarboksylsyrederivater
NO306159B1 (no) 5-arylisoksazol-4-substituerte 2-aminokarboksylsyreforbindelser
NO873514L (no) Fremgangsmaate for fremstilling av farmasoeytisk aktive forbindelser.
NO873628L (no) 2,3-dihydro-1h-fenalen-2-amino-forbindelser som antipsykotiske legemidler.
DK256689D0 (da) 1,2-dithiol-3-thion-s-oxid-forbindelser til anven delse som laegemidler
NO893326D0 (no) Fremgangsmaate for noeytralisering av svovelsyre inneholdende sinkioner.
DK0876367T3 (da) Trans apovincaminsyreesterderivater som lægemidler
DK162631C (da) Forbindelse, betegnet fr-900216, til anvendelse som terapeutisk aktivt stof, farmaceutisk praeparat indeholdende forbindelsen samt anvendelse af forbindelsen
DE3680011D1 (de) Tabletten fuer wirkstoffkombinationen.
DE9307393U1 (de) Tablette mit verbesserter Bioverfügbarkeit, enthaltend Dichlormethylendiphosphonsäure als Wirkstoff
NO904496L (no) Fremgangsmaate for fremstilling av optisk aktive tiazetokinolin-3-karboksylsyreforbindelser.